142 related articles for article (PubMed ID: 18559616)
21. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets.
Werther K; Christensen IJ; Nielsen HJ
Scand J Clin Lab Invest; 2002; 62(5):343-50. PubMed ID: 12387579
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.
Del Vecchio M; Mortarini R; Canova S; Di Guardo L; Pimpinelli N; Sertoli MR; Bedognetti D; Queirolo P; Morosini P; Perrone T; Bajetta E; Anichini A
Clin Cancer Res; 2010 Dec; 16(23):5862-72. PubMed ID: 21030496
[TBL] [Abstract][Full Text] [Related]
23. Preparation of highly concentrated and white cell-poor platelet-rich plasma by plateletpheresis.
Zimmermann R; Reske S; Metzler P; Schlegel A; Ringwald J; Eckstein R
Vox Sang; 2008 Jul; 95(1):20-5. PubMed ID: 18444946
[TBL] [Abstract][Full Text] [Related]
24. Storage of apheresis platelet concentrates after manual replacement of >95% of plasma with PAS 5.
Morrison A; McMillan L; Radwanski K; Blatchford O; Min K; Petrik J
Vox Sang; 2014 Oct; 107(3):247-53. PubMed ID: 24801569
[TBL] [Abstract][Full Text] [Related]
25. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients.
Salgado R; Vermeulen PB; Benoy I; Weytjens R; Huget P; Van Marck E; Dirix LY
Br J Cancer; 1999 May; 80(5-6):892-7. PubMed ID: 10360671
[TBL] [Abstract][Full Text] [Related]
26. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.
Janetzko K; Lin L; Eichler H; Mayaudon V; Flament J; Klüter H
Vox Sang; 2004 May; 86(4):239-45. PubMed ID: 15144528
[TBL] [Abstract][Full Text] [Related]
27. Vascular endothelial growth factor, fibroblast growth factor 2, platelet derived growth factor and transforming growth factor beta released in human dental pulp following orthodontic force.
Derringer KA; Linden RW
Arch Oral Biol; 2004 Aug; 49(8):631-41. PubMed ID: 15196981
[TBL] [Abstract][Full Text] [Related]
28. Paired in vitro and in vivo comparison of apheresis platelet concentrates stored in platelet additive solution for 1 versus 7 days.
Shanwell A; Diedrich B; Falker C; Jansson B; Sandgren P; Sundkvist L; Svensson L; Vesterinen M; Gulliksson H
Transfusion; 2006 Jun; 46(6):973-9. PubMed ID: 16734814
[TBL] [Abstract][Full Text] [Related]
29. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor.
Salven P; Orpana A; Joensuu H
Clin Cancer Res; 1999 Mar; 5(3):487-91. PubMed ID: 10100697
[TBL] [Abstract][Full Text] [Related]
30. Platelet storage lesion: an update on the impact of various leukoreduction processes on the biological response modifiers.
Seghatchian J
Transfus Apher Sci; 2006 Feb; 34(1):125-30. PubMed ID: 16376152
[TBL] [Abstract][Full Text] [Related]
31. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
32. Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma.
Sundman EA; Cole BJ; Fortier LA
Am J Sports Med; 2011 Oct; 39(10):2135-40. PubMed ID: 21846925
[TBL] [Abstract][Full Text] [Related]
33. In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days.
Moog R; Fröhlich A; Mayaudon V; Lin L
J Clin Apher; 2004; 19(4):185-91. PubMed ID: 15597347
[TBL] [Abstract][Full Text] [Related]
34. Slow release of growth factors and thrombospondin-1 in Choukroun's platelet-rich fibrin (PRF): a gold standard to achieve for all surgical platelet concentrates technologies.
Dohan Ehrenfest DM; de Peppo GM; Doglioli P; Sammartino G
Growth Factors; 2009 Feb; 27(1):63-9. PubMed ID: 19089687
[TBL] [Abstract][Full Text] [Related]
35. [Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].
Smolej L; Andrýs C; Krejsek J; Belada DZ; Zák P; Siroký O; Malý J
Vnitr Lek; 2007 Nov; 53(11):1171-6. PubMed ID: 18277626
[TBL] [Abstract][Full Text] [Related]
36. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
37. Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology.
Keyes KA; Mann L; Cox K; Treadway P; Iversen P; Chen YF; Teicher BA
Cancer Chemother Pharmacol; 2003 Apr; 51(4):321-7. PubMed ID: 12721760
[TBL] [Abstract][Full Text] [Related]
38. Early storage lesions in apheresis platelets are induced by the activation of the integrin αIIbβ₃ and focal adhesion signaling pathways.
Thiele T; Iuga C; Janetzky S; Schwertz H; Gesell Salazar M; Fürll B; Völker U; Greinacher A; Steil L
J Proteomics; 2012 Dec; 76 Spec No.():297-315. PubMed ID: 22634086
[TBL] [Abstract][Full Text] [Related]
39. Challenges for patient selection with VEGF inhibitors.
Longo R; Gasparini G
Cancer Chemother Pharmacol; 2007 Jul; 60(2):151-70. PubMed ID: 17370072
[TBL] [Abstract][Full Text] [Related]
40. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
